日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Health-related quality of life in immunocompromised adults with mild-moderate COVID-19 treated with nirmatrelvir-ritonavir: results from the randomized, double-blinded EPIC-IC trial

接受尼马曲韦-利托那韦治疗的轻中度 COVID-19 免疫功能低下成人患者的健康相关生活质量：来自随机、双盲 EPIC-IC 试验的结果

期刊:Health and Quality of Life Outcomes
影响因子:3.4
doi:10.1186/s12955-026-02518-8
Mokgokong, Ruth; Cislo, Paul; Tudone, Elena; Weinstein, Edward; Cappelleri, Joseph C
免疫/内分泌
发表日期：2026
文献求助 收藏

Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial

免疫功能低下成人新冠肺炎患者接受尼马替韦-利托那韦治疗后症状缓解/消退及恢复正常健康/活动：EPIC-IC试验结果

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-025-01228-w
Mokgokong, Ruth; Cislo, Paul; Tudone, Elena; Weinstein, Edward; Cappelleri, Joseph C
肺炎
新冠
免疫/内分泌
微生物学
发表日期：2025
文献求助 收藏

Pharmacokinetic profile of defibrotide in patients with renal impairment

地夫布罗肽在肾功能不全患者中的药代动力学特征

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S112181
Tocchetti, Paola; Tudone, Elena; Marier, Jean-Francois; Marbury, Thomas C; Zomorodi, Katie; Eller, Mark
发表日期：2016
文献求助 收藏